TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

Abstract Background Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9–24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for pe...

Full description

Bibliographic Details
Main Authors: Catherine Berry, Philipp du Cros, Katherine Fielding, Suzanne Gajewski, Emil Kazounis, Timothy D. McHugh, Corinne Merle, Ilaria Motta, David A. J. Moore, Bern-Thomas Nyang’wa
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Trials
Subjects:
Multidrug-resistant tuberculosis
Bedaquiline
Linezolid
Clofazimine
Pretomanid
Moxifloxacin
Online Access:https://doi.org/10.1186/s13063-022-06331-8

Internet

https://doi.org/10.1186/s13063-022-06331-8

Similar Items